Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).

@article{Xu2017RituximabER,
  title={Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).},
  author={Zhi-hong Xu and Cai-Hong Liu and Jun-biao Hang and Bei-li Gao and Jia-an Hu},
  journal={Cancer biomarkers : section A of Disease markers},
  year={2017},
  volume={20 4},
  pages={
          581-588
        }
}
Tyrosine kinase inhibitors (TKIs), a novel group of target-specific anti lung cancer drugs, have recently been found to resistant to some NSCLC cells which have the T790M EGFR mutation. However, recent investigations on the therapies of resistance to EGFR-TKIs are very limited. Therefore, it is important to develop more effective therapies to reverse EGFR-TKIs resistance. In our present study, erlotinib was used as the TKIs drug and the effects of the erlotinib on cell growth were evaluated… CONTINUE READING
1
Twitter Mention